Fas (CD95) and bcl-2 expression in active skin lesions of Behcet's disease

被引:14
作者
Baris, YS [1 ]
Yildiz, L
Sentürk, N
Kandemir, B
机构
[1] Ondokuz Mayis Univ, Sch Med, Dept Pathol, TR-55139 Kurupelit, Turkey
[2] Ondokuz Mayis Univ, Sch Med, Dept Dermatol, TR-55139 Kurupelit, Turkey
关键词
bcl-2; Behcet's disease; CD95; Fas;
D O I
10.1111/j.1468-3083.2005.01250.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Over-expression of bcl-2 in lymphocytes has an important role in some immunological and inflammatory diseases. Fas (CD95) is a cell surface molecule that mediates receptor-triggered apoptosis in various cells including autoreactive T cells. In this study we investigated bcl-2 and Fas (CD95) expression in dermal lymphocytes in active skin lesions of Behcet's disease (BD) and in skin biopsy samples with chronic, non-specific inflammations. Tissue sections of 29 skin lesions of Behcet's disease and of 10 chronic non-spesific inflammatory process cases from the archives of the Ondokuz Mayis University's Pathology Department were immunohistochemically stained for bcl-2 and Fas (CD95), and lymphocytes in the dermal infiltrate were evaluated for cytoplasmic staining. bcl-2 staining was observed in the skin lesions of 22 cases (75.8%) of Behcet's disease. bcl-2 staining was detected in two (20%) control skin biopsy samples with non-specific chronic inflammation. Fas (CD95) positivity was not detected in lymphocytes in Behcet's disease-related skin lesions. Fas (CD95) staining was observed in only three skin biopsy samples with non-specific chronic inflammation. bcl-2 and Fas (CD95) staining values in Behcet's and non-specific inflammation groups were significantly different (P < 0.01); differences in the bcl-2 staining values between Behcet's patients with mucocutaneous involvement only and mucocutaneous and other systemic involvements were not significant (P > 0.05). Expression of bcl-2 and loss of Fas (CD95) expression in dermal lymphocytes may play a role in the development of skin lesions and may account for the chronic course with periodic exacerbations in BD.
引用
收藏
页码:569 / 572
页数:4
相关论文
共 15 条
[1]
PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE [J].
CHENG, JH ;
ZHOU, T ;
LIU, CD ;
SHAPIRO, JP ;
BRAUER, MJ ;
KIEFER, MC ;
BARR, PJ ;
MOUNTZ, JD .
SCIENCE, 1994, 263 (5154) :1759-1762
[2]
ELDER D, 1997, HISTOPATHOLOGY SKIN
[3]
Hamzaoui A, 1996, CLIN EXP RHEUMATOL, V14, P106
[4]
Levels of soluble Fas/APO-1 in patients with Behcet's disease [J].
Hamzaoui, K ;
Hamzaoui, A ;
Zakraoui, L ;
Chabbou, A .
MEDIATORS OF INFLAMMATION, 1998, 7 (02) :111-114
[5]
BCL-2 IS AN INNER MITOCHONDRIAL-MEMBRANE PROTEIN THAT BLOCKS PROGRAMMED CELL-DEATH [J].
HOCKENBERY, D ;
NUNEZ, G ;
MILLIMAN, C ;
SCHREIBER, RD ;
KORSMEYER, SJ .
NATURE, 1990, 348 (6299) :334-336
[6]
HOCKENBERY D, 1990, NATURE, V22, P348
[7]
Lu QL, 1996, HUM PATHOL, V27, P102, DOI 10.1016/S0046-8177(96)90362-7
[8]
Behçet's disease: immunopathologic and therapeutic aspects. [J].
Meador R. ;
Ehrlich G. ;
Von Feldt J.M. .
Current Rheumatology Reports, 2002, 4 (1) :47-54
[9]
Miret C, 1999, ANTICANCER RES, V19, P3073
[10]
AUTOIMMUNE-DISEASE - A PROBLEM OF DEFECTIVE APOPTOSIS [J].
MOUNTZ, JD ;
WU, JG ;
CHENG, JH ;
ZHOU, T .
ARTHRITIS AND RHEUMATISM, 1994, 37 (10) :1415-1420